José Presa
A5017801540- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Colorectal Cancer Treatments and Studies
- Liver Diseases and Immunity
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatitis C virus research
- Cancer Immunotherapy and Biomarkers
- Organ Transplantation Techniques and Outcomes
- Chronic Lymphocytic Leukemia Research
- Economic and Financial Impacts of Cancer
- Pediatric Hepatobiliary Diseases and Treatments
- Gallbladder and Bile Duct Disorders
- Gastric Cancer Management and Outcomes
- Hepatitis B Virus Studies
- Multiple and Secondary Primary Cancers
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Treatment and Management
- Heavy Metal Exposure and Toxicity
- Cancer Mechanisms and Therapy
- Metabolism, Diabetes, and Cancer
- Hepatitis Viruses Studies and Epidemiology
- Trace Elements in Health
- Electrolyte and hormonal disorders
- Cancer, Lipids, and Metabolism
Centro Hospitalar de Trás os Montes e Alto Douro
2013-2025
Direção Geral do Território
2022-2024
Fundación Ciencias Exactas y Naturales
2024
University of Buenos Aires
2024
Experimental Medicine and Biology Institute
2024
Consejo Nacional de Investigaciones Científicas y Técnicas
2024
Association for the Development of Douro Viticulture
2013-2023
Infraestruturas de Portugal (Portugal)
2018
Hospital Universitario Virgen de las Nieves
2009
The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.A total 1381 had PD at therapy. 917 received as treatment, 464 bevacizumab first-line.49.6% a therapy without any statistical difference in overall survival (OS) between (20.6months) (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After first-line, there wasn't...
Background and aims Current prognostic scores of patients with acutely decompensated cirrhosis (AD), particularly those acute-on-chronic liver failure (ACLF), underestimate the risk mortality. This is probably because systemic inflammation (SI), major driver AD/ACLF, not reflected in scores. SI induces metabolic changes, which impair delivery necessary energy for immune reaction. investigation aimed to identify metabolites associated short-term (28-day) death design metabolomic models....
The burden of nonalcoholic fatty liver disease (NAFLD) is increasing, with an estimated prevalence in Europe 20-30%. Although most patients present simple steatosis, some progress to advanced fibrosis, cirrhosis, and hepatocellular carcinoma. Definite diagnosis staging require biopsy, which not feasible given the high NAFLD. As such, several noninvasive tools have been formulated. However, date, none validated Portuguese population. aim this study was determine diagnostic accuracy aspartate...
Introduction: The prognostic nutritional index (PNI) is a multiparametric score introduced by Onodera based on the blood levels of lymphocytes and albumin in patients with gastrointestinal neoplasms. Regarding hepatocellular carcinoma (HCC), its role has been shown treated sorafenib lenvatinib. aim this real-world study was to investigate association between clinical outcomes PNI being atezolizumab plus bevacizumab. Methods: overall cohort multicentric included 871 consecutive HCC from 5...
The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post hoc analyses IMbrave-150 metanalyses clinical trials PD-1/PD-L1 blockers. As a results, it not clear whether the first-line systemic treatment atezolizumab plus bevacizumab (A + B) equally effective viral nonviral patients.
Summary Background Obeticholic acid (OCA) was recently approved as the only on‐label alternative for patients with primary biliary cholangitis (PBC) intolerance or suboptimal response to ursodeoxycholic (UDCA). However, few data are available outside clinical trials. Aim To assess effectiveness and safety of OCA in a real‐world cohort non‐effective UDCA therapy. Methods Open‐label, prospective, real‐world, multicentre study, enrolling consecutive who did not meet Paris II criteria, from 18...
Abstract Background The current standard of treatment in primary biliary cholangitis (PBC) is ursodeoxycholic acid (UDCA), although a considerable proportion patients show incomplete response resulting disease progression. Objective This study aimed to assess the prevalence UDCA and determine associated patients' characteristics. Methods Patients with PBC as main diagnosis were included from national multicentric patient registry—Liver.pt. Main endpoints according Barcelona, Paris I II...
Summary Background Suboptimal response to ursodeoxycholic acid occurs in 40% of primary biliary cholangitis (PBC) patients, affecting survival. Achieving a deep (normalisation alkaline phosphatase [ALP] and bilirubin ≤0.6 upper limit normal) improves Yet, the long‐term effectiveness second‐line treatments remains uncertain. Aims To evaluate obeticholic (OCA) ± fibrates. Focusing on biochemical (ALP ≤1.67 times normal, with decrease at least 15% from baseline normal levels), normalisation...
579 Background: Atezolizumab plus bevacizumab and lenvatinib have not been compared in a randomized controlled trial. We conducted retrospective multi-center study to compare the clinical efficacy safety of atezolizumab with as first-line treatment for patients unresectable HCC real-world scenario. Methods: Clinical features were balanced through inverse probability weighting (IPTW) methodology, which weights patients' characteristics measured outcomes each patient both arms. Overall...
Abstract Introduction Overweight is a negative prognostic factor in the general population long term. However, role of body mass index (BMI) short‐mid term advanced tumours unclear. The present analysis investigates BMI weight classes large sample patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first‐line treatment. Methods Material cohort included consecutive BCLC‐c BCLC‐B from multicenter international study group who received therapy. Population was...
Abstract Atezolizumab plus bevacizumab (AB) and lenvatinib can be alternatively used as first‐line systemic treatment of unresectable hepatocellular carcinoma (HCC). However, no direct comparison the two regimens has been performed in randomized clinical trials, making identification baseline differential predictors response major relevance to tailor best therapeutic option each patient. Baseline laboratory characteristics real‐world AB‐treated HCC patients were analyzed uni‐ multivariate...
<b><i>Background and Aims:</i></b> Liver cirrhosis (LC) is the end stage of multiple processes that lead to hepatic failure 10th most common cause death in Western world. Bacterial infections are one important clinical problems patients with LC, as their underlying immune status compromised. Approximately 60% bacterial cirrhotic community acquired (CA) 40% nosocomial. The spontaneous peritonitis (SBP) (25%), urinary tract infection (UTI) (20%), pneumonia (15%),...
In the context of patients with hepatocellular carcinoma (HCC) treated systemic therapy, correlation between appearance adverse events (AEs) and reported efficacy outcomes is well-known widely investigated. From other pathological settings, we are aware prognostic predictive value occurrence immune-related AEs in immune-checkpoint inhibitors.
Introduction: The most frequently used first-line treatment in patients with advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab. Upon progression after this treatment, the standard of care many countries sorafenib, due to lack reimbursement for other drugs. Several randomized trials are currently underway clarify best second-line therapy HCC. This real-world study aimed compare outcomes reached by lenvatinib and sorafenib setting. Methods: overall cohort included 891...